drugset / Trial / NCT00800215

A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927

NCT00800215

Phase 2 Completed 60 enrolled UCB Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial was to evaluate the safety and tolerability of SPM 927 when given as iv infusions compared with oral administration of the same dose strengths in subjects who were receiving oral SPM 927 for partial seizures with or without secondary generalization. Trial procedures will include medical history update, physical/ neurological exams, ECGs, blood /urine sample collections and seizure diary completion. Subjects completing the trial will return to the OLE trial to resume dosing with oral SPM 927.

Timeline

Start
2004-03-04
Primary completion
2004-08-17
Completion
2004-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacosamide Other / unclassified Intravenous

Indications